Literature DB >> 361200

Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states.

M S Loewenstein, N Zamcheck.   

Abstract

Elevated circulating CEA levels occur in patients with benign gastrointestinal and hepatic disorders. These are usually less than 10 ng/ml. Of clinical importance is the influence of liver disease on the interpretation of CEA. At least 50% of patients with severe benign hepatic disease have elevated CEA levels, most often active alcoholic cirrhosis, and also chronic active and viral hepatitis, and cryptogenic and biliary cirrhosis. Patients with benign extrahepatic biliary obstruction may have increased plasma CEA, the highest in patients with co-existent cholangitis and especially liver abscess. The liver appears to be essential for the metabolism and/or excretion of CEA. Hence, liver work-up is needed to assess any patient with an elevated CEA. A damaged liver may further augment elevated CEA levels due to cancer. The increased circulating CEA observed in some patients with active ulcerative colitis tends to correlate with severity and extent of disease and usually returns to normal with remission. CEA levels also may be mildly elevated in patients with pancreatitis and in adults with colonic polyps. Smoking may contribute to the increased CEA levels seen in patients with alcoholic liver disease and pancreatitis. Therefore, in interpreting mildy elevated circulating CEA levels in patients with GI tract diseases, one must consider benign as well as malignant etiologies.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 361200     DOI: 10.1002/1097-0142(197809)42:3+<1412::aid-cncr2820420805>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  The use and potential of serum tumour markers, new and old.

Authors:  S E Bates
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

2.  Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective.

Authors:  Upender Manne; Trafina Jadhav; Balananda-Dhurjati Kumar Putcha; Temesgen Samuel; Shivani Soni; Chandrakumar Shanmugam; Esther A Suswam
Journal:  Curr Colorectal Cancer Rep       Date:  2016-09-20

3.  Serologic markers in the diagnosis and management of pancreatic carcinoma.

Authors:  D K Podolsky
Journal:  World J Surg       Date:  1984-12       Impact factor: 3.352

4.  Clinical Usefulness of Serum CYFRA 21-1 in Patients with Colorectal Cancer.

Authors:  Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-08-06

5.  Serum CEA levels facilitate detection of recurrences of cancer in patients after gastrectomy.

Authors:  R Tamada; Y Hiramoto; S Tsujitani; T Nozuka; T Okamura; H Masuda; K Sugimachi; K Inokuchi
Journal:  Jpn J Surg       Date:  1985-01

6.  Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer.

Authors:  Raja R Narayan; Debra A Goldman; Mithat Gonen; Jonathan Reichel; Kety H Huberman; Sandeep Raj; Agnes Viale; Nancy E Kemeny; Peter J Allen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham
Journal:  Ann Surg Oncol       Date:  2019-01-31       Impact factor: 5.344

7.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

8.  Carcinoembryonic antigen: physician attitudes, patterns of use, and impact upon patient care.

Authors:  S L Vest; J K Roche
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

9.  Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.

Authors:  R Molina; G Zanón; X Filella; F Moreno; J Jo; M Daniels; M L Latre; N Giménez; J Pahisa; M Velasco
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction.

Authors:  Kimberly Moore Dalal; Yanghee Woo; Kaitlyn Kelly; Charles Galanis; Mithat Gonen; Yuman Fong; Daniel G Coit
Journal:  Gastric Cancer       Date:  2009-01-08       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.